AbbVie Loses Chancery Fight For Takeda Contract Injunction

Bizar Male
Law360 (September 8, 2021, 3:48 PM EDT) — AbbVie Endocrine Inc. has lost a bid for a Delaware Chancery Court injunction that would bind Japan’s Takeda Pharmaceutical Co. Ltd. to North American delivery targets for a globally important drug as part of an eventual contract breach award, despite AbbVie’s claims of irreparable harm risks.

Vice Chancellor Sam Glasscock III found in a 24-page post-trial opinion Tuesday that approval and enforcement of AbbVie’s injunction request and oversight of Takeda’s production and distribution mandates for the drug Lupron would be unworkable regardless of the court’s corporate and commercial law clout.

“The complexity of the business judgments involved, and the involvement of…

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Next Post

Prosecuting Attorney Steve Alm, gives criminals a fair warning, in a effort to keep drug activity low on Oahu

HONOLULU (KHON2) – “For anyone working in Chinatown, you’re going to get arrested,” said Honolulu Prosecuting Attorney Steve Alm, who was calling out drug dealers, in a press conference in front of Kehaulike Market held on Wednesday. “We are going to prosecute you. The business and residents down here deserve […]